Nektar Therapeutics (NKTR) Price & Analysis

Compare

1,519 Followers

NKTR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.49 - $61.15

Previous CloseN/A

Volume706.47K

Average Volume (3M)1.22M

Market Cap

$1.12B

Enterprise Value$364.84M

Total Cash (Recent Filing)$175.90M

Total Debt (Recent Filing)$96.16M

Price to Earnings (P/E)―

Beta3.88

Next Earnings

Nov 06, 2025

EPS Estimate

-2.74

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.95

Shares Outstanding19,018,574

10 Day Avg. Volume1,303,586

30 Day Avg. Volume1,217,428

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.33

Enterprise Value/Revenue4.87

Enterprise Value/Gross Profit5.86

Enterprise Value/Ebitda-4.07

Forecast

1Y Price Target

$104.50

Price Target Upside77.57% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Efficacy In TrialsContinuous treatment with rezpeg deepens responses in AD patients.

Financial PerformanceFor 2Q25, the company reported revenue of $11.2M and a net loss of $2.95 per share, compared to the consensus estimated revenue of $9.5M and a net loss of $3.03.

Therapeutic PotentialRezpeg achieved statistical significance on the primary endpoint and all key secondary endpoints, indicating its strong therapeutic potential.

Bears Say

Differentiation ConcernsThe newly disclosed data does not materially alter the view on rezpeg as questions around its differentiation remain unanswered.

Market PositionAnalysts struggle with where rezpeg might fit in the treatment paradigm as the phase II REZOLUTE results do not support its use as a front-line biologic in AD.

Nektar Therapeutics News

Nektar price target raised to $99 from $69 at Jefferies

Jefferies analyst Roger Song raised the firm’s price target on Nektar (NKTR) to $99 from $69 and keeps...

15d ago

NKTR

Nektar’s rezpegaldesleukin shows efficacy in Phase 2b atopic dermatitis trial

Nektar (NKTR) Therapeutics announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway...

15d ago

NKTR

Nektar management to meet with Piper Sandler

Meeting to be held in New York on September 11 hosted by Piper Sandler. Published first on TheFly...

25d ago

NKTR

Sanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher

Shares of Nektar Therapeutics (NKTR) jumped on Thursday after Sanofi reported the first headline data for amlitelimab from...

29d ago

SNY

AMGN

Piper says competitor AD data reinforces Nektar’s REZPEG differentiated profile

Piper Sandler notes that Sanofi (SNY) released data from amlitelimab’s Phase 3 COAST 1 in moderate-to-severe atopic dermatitis...

29d ago

SNY

NKTR

Salesforce slides, Figma flops after earnings: Morning Buzz

Stock were mixed and little changed in early trading, reflecting uncertainty ahead of the highly anticipated Friday jobs...

29d ago

Nektar jumps after Sanofi data misses expectations

Shares of Nektar (NKTR) are moving higher after Sanofi (SNY) reported Phase 3 data for amlitelimab, its experimental...

29d ago

SNY

NKTR

Nektar Therapeutics Reveals Promising Phase 2b Study Results

The latest announcement is out from Nektar Therapeutics ( ($NKTR) ). On September 18, 2025, Nektar Therapeutics announced...

15d ago

NKTR

Nektar Therapeutics’ Earnings Call Highlights Growth Potential

Nektar Therapeutics (($NKTR)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

NKTR

Nektar price target raised to $98 from $90 at Oppenheimer

Oppenheimer raised the firm’s price target on Nektar (NKTR) to $98 from $90 and keeps an Outperform rating...

2M ago

NKTR

Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance

Analyst Arthur He CFA from H.C. Wainwright reiterated a Buy rating on Nektar Therapeutics and keeping the price...

2M ago

NKTR

Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments

William Blair analyst Andy Hsieh has reiterated their neutral stance on NKTR stock, giving a Hold rating on...

2M ago

NKTR

Nektar Therapeutics Reports Q2 2025 Financial Results

Nektar Therapeutics ( ($NKTR) ) has released its Q2 earnings. Here is a breakdown of the information Nektar...

2M ago

NKTR

Nektar reports Q2 adjusted EPS ($2.78), consensus ($3.12)

Reports Q2 revenue $11.2M, consensus $9.42M. “This quarter, we announced transformative data for rezpegaldesleukin from the Phase 2b...

2M ago

NKTR

NKTR FAQ

What was Nektar Therapeutics’s price range in the past 12 months?

Nektar Therapeutics lowest stock price was $6.49 and its highest was $61.15 in the past 12 months.

What is Nektar Therapeutics’s market cap?

Nektar Therapeutics’s market cap is $1.12B.

When is Nektar Therapeutics’s upcoming earnings report date?

Nektar Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 34 days.

How were Nektar Therapeutics’s earnings last quarter?

Nektar Therapeutics released its earnings results on Aug 07, 2025. The company reported -$2.95 earnings per share for the quarter, beating the consensus estimate of -$3.028 by $0.078.

Is Nektar Therapeutics overvalued?

According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nektar Therapeutics pay dividends?

Nektar Therapeutics does not currently pay dividends.

What is Nektar Therapeutics’s EPS estimate?

Nektar Therapeutics’s EPS estimate is -2.74.

How many shares outstanding does Nektar Therapeutics have?

Nektar Therapeutics has 19,018,574 shares outstanding.

What happened to Nektar Therapeutics’s price movement after its last earnings report?

Nektar Therapeutics reported an EPS of -$2.95 in its last earnings report, beating expectations of -$3.028. Following the earnings report the stock price went up 6.023%.

Which hedge fund is a major shareholder of Nektar Therapeutics?

Currently, no hedge funds are holding shares in NKTR

Nektar Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-440.80%

Trailing 12-Months

Asset Growth

-39.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Nektar Therapeutics (NKTR) Earnings & Revenues

Historic Earnings Reports

NKTR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call was largely positive, with strong data for REZPEG in atopic dermatitis and a solid financial position enabling future clinical advancements. The company is actively preparing for Phase III trials and expanding its market potential. However, challenges such as net losses, injection site reactions, and ongoing litigation with Lilly were noted.View all NKTR earnings summaries

NKTR Stock 12 Month Forecast

Average Price Target

$104.50

▲(77.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","121":"$121","36.25":"$36.3","64.5":"$64.5","92.75":"$92.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":104.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$104.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$98.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,36.25,64.5,92.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.85,63.55384615384615,68.25769230769231,72.96153846153847,77.66538461538462,82.36923076923077,87.07307692307693,91.77692307692308,96.48076923076923,101.1846153846154,105.88846153846154,110.59230769230768,115.29615384615386,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.85,62.361538461538466,65.87307692307692,69.38461538461539,72.89615384615385,76.40769230769232,79.91923076923078,83.43076923076923,86.9423076923077,90.45384615384616,93.96538461538461,97.47692307692307,100.98846153846154,{"y":104.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.85,61.861538461538466,64.87307692307692,67.88461538461539,70.89615384615385,73.90769230769232,76.91923076923078,79.93076923076923,82.9423076923077,85.95384615384616,88.96538461538461,91.97692307692307,94.98846153846154,{"y":98,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.45,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":17.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >